Autopsy report · NCT00868790

A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)

“Upon interim analysis, sufficient data was accrued to assess study hypotheses.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 4 months before it stopped.
• 118 participants enrolled.
• Results were posted on the registry 6 years 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Merck Sharp & Dohme LLC

Sponsor type

Industry

Conditions

Type 2 Diabetes Mellitus

Interventions

MK-3577; Placebo to MK-3577; Metformin; Placebo to Metformin

Participants

118

Trials that died the same way

• Feeding After Neonate Surgery Review
  “sufficient data gathered for study conclusion” (74% match in meaning)
• The Role of Post-traumatic Inhibition of the Innate and Adaptive Immune System in the Development of Infectious Complications in Severely Injured Patients
  “Interim analysis provided enough data” (70% match in meaning)
• Verapamil vs Steroid to Prevent Keloid Recurrence
  “Objective of study achieved after interim analysis.” (66% match in meaning)
• Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer
  “Interim analysis determined the study did not meet criteria to proceed” (65% match in meaning)
• Efficacy Study of Polyunsaturated Fatty Acids in Children and Adolescents With Attention Deficit/ Hyperactivity Disorder
  “The sample size of the planned interims analysis was achieved” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.